MEREDITH QUARLES: Open Payments
NPI 1104225101 · APPOMATTOX, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,213 in 65 payments from 15 companies in 2025. Trend: 2023 $2,386 · 2024 $1,857 · 2025 $1,213
Food & beverage: $1,213
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $247 |
| AstraZeneca Pharmaceuticals LP | 8 | $230 |
| Novo Nordisk Inc | 13 | $218 |
| Lilly USA, LLC | 6 | $116 |
| PFIZER INC. | 4 | $79 |
| Amgen Inc. | 5 | $75 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $54 |
| Exact Sciences Corporation | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| Astellas Pharma US Inc | 2 | $27 |
Products named: Wegovy, FARXIGA, QULIPTA, MOUNJARO, UBRELVY, NURTEC ODT, CAPLYTA, VRAYLAR.
Industry payments across VA — which companies pay providers there.
